Lilly’s Strong Alimta Pivotal Study Obviated Need For Second Trial – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The significant survival benefit seen with Alimta in Lilly’s sole pivotal mesothelioma trial appears to have obviated FDA’s need for efficacy data from a second study.
You may also be interested in...
Alimta Mesothelioma Indication: Response Not Acceptable Endpoint, FDA Says
Response is not an acceptable primary endpoint for approval in mesothelioma, FDA said in review documents for Lilly’s oncologic agent Alimta.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product